Details
Stereochemistry | ACHIRAL |
Molecular Formula | C35H32N6O4 |
Molecular Weight | 600.6664 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC2=CN=CC=C2N1CC3CCN(CC3)C(=O)\C=C(\C4=CC=CC=C4)C5=CC=C(C=C5)\N=N\C6=CC=C(O)C(=C6)C(O)=O
InChI
InChIKey=AYEAMZDTWLXZIJ-RKOUKRECSA-N
InChI=1S/C35H32N6O4/c1-23-37-31-21-36-16-13-32(31)41(23)22-24-14-17-40(18-15-24)34(43)20-29(25-5-3-2-4-6-25)26-7-9-27(10-8-26)38-39-28-11-12-33(42)30(19-28)35(44)45/h2-13,16,19-21,24,42H,14-15,17-18,22H2,1H3,(H,44,45)/b29-20-,39-38+
Dersalazine is a locally-acting compound. It is a potent platelet activating factor (PAF)-antagonist. Dersalazine inhibited IL-1beta or TNF-alpha production in THP-1 or U937 cells, respectively. Dersalazine sodium reduced colonic proinflammatory cytokines IL-1b, IL-6, and IL-17 in dextran sodium sulphate (DSS)–induced colitis. After oral administration, dersalazine sodium is mostly unabsorbed until it reaches the large bowel where the azo bond is reduced by bacteria releasing the active compound. Dersalazine had been in phase I clinical trial for the treatment of ulcerative colitis. No serious adverse reactions were detected in clinical trial. However, no recent development has been reported.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25192498
1200 mg/12 h for 4 weeks
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C308
Created by
admin on Sat Dec 16 16:52:05 GMT 2023 , Edited by admin on Sat Dec 16 16:52:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8194
Created by
admin on Sat Dec 16 16:52:05 GMT 2023 , Edited by admin on Sat Dec 16 16:52:05 GMT 2023
|
PRIMARY | |||
|
WS1IH75AJT
Created by
admin on Sat Dec 16 16:52:05 GMT 2023 , Edited by admin on Sat Dec 16 16:52:05 GMT 2023
|
PRIMARY | |||
|
9808813
Created by
admin on Sat Dec 16 16:52:05 GMT 2023 , Edited by admin on Sat Dec 16 16:52:05 GMT 2023
|
PRIMARY | |||
|
188913-58-8
Created by
admin on Sat Dec 16 16:52:05 GMT 2023 , Edited by admin on Sat Dec 16 16:52:05 GMT 2023
|
PRIMARY | |||
|
DB06251
Created by
admin on Sat Dec 16 16:52:05 GMT 2023 , Edited by admin on Sat Dec 16 16:52:05 GMT 2023
|
PRIMARY | |||
|
300000034116
Created by
admin on Sat Dec 16 16:52:05 GMT 2023 , Edited by admin on Sat Dec 16 16:52:05 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106406
Created by
admin on Sat Dec 16 16:52:05 GMT 2023 , Edited by admin on Sat Dec 16 16:52:05 GMT 2023
|
PRIMARY | |||
|
C77949
Created by
admin on Sat Dec 16 16:52:05 GMT 2023 , Edited by admin on Sat Dec 16 16:52:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD